Utah is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
NCT06212323
Recruiting
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Conditions: Smoldering Multiple Myeloma
Register for Updates
Guided Meditation During Radiation Therapy for Brain Tumors
NCT06165653
Recruiting
The goal of this interventional treatment study is to assess the anxiolytic effect of providing guided meditation during radiation treatment (RT) in patients with brain tumors. The main question it aims to answer is: • What is the change in acute anxiety in participants receiving the mindfulness intervention during radiation therapy compared to standard of care control conditions? Participants will be asked to participate in a 5-minute, audio-recorded mindfulness practice that will be played... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Brain Neoplasms
Register for Updates
Bortezomib in Patients with Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion
NCT06029998
Recruiting
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion. The main question\[s\] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants. Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles. Each cycle is about 21 days.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Comparative Effectiveness of Online 8-session CBT Vs. 1-Session Empowered Relief for Chronic Pain - the PROGRESS Study
NCT05612750
Recruiting
The purpose of this study is to conduct a pragmatic clinical trial comparing the effectiveness of: (1) 8-week cognitive behavioral therapy for chronic pain (pain-CBT; sixteen hours total treatment time); and (2) a 1-session pain relief skills intervention for chronic pain (Empowered Relief; two hours total treatment time).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Intermountain Healthcare, Salt Lake City, Utah
Conditions: Pain, Chronic, Lupus, Pelvic Pain
Register for Updates
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
Study in Parkinson Disease of Exercise
NCT04284436
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Parkinson Disease
Register for Updates
Nerve Transfer to Improve Function in High Level Tetraplegia
NCT06288763
Recruiting
The goal of this observational study is to determine if nerve transfer surgeries improve upper extremity function and quality of life in patients with a high level cervical spinal cord injury. Participants will: * undergo standard of care pre- and post-op testing and study exams * complete pre- and post-questionnaires * undergo standard of care nerve transfer surgeries * follow-up with surgeon at 6/12/18/24/36 and potentially at 48 months * attend therapy at local therapist for up to 2 years p... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/11/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Cervical Spinal Cord Injury, Tetraplegia
Register for Updates
Progression of Early Atrophic Lesions
NCT05959005
Recruiting
Early atrophic age-related macular degeneration (AMD) represents an important time window in the course of so far untreatable atrophic AMD, as patients typically experience only some degree of visual dysfunction, while being at significant risk for marked further loss of vision. To allow the precise evaluation of upcoming therapeutic interventions, a better understanding of the manifestation and variable disease progression is needed. This project aims to investigate refined tools to detect and... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/11/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Age-Related Macular Degeneration
Register for Updates
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493
Recruiting
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
NCT05392114
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/08/2024
Locations: Ionis Investigative Site, Murray, Utah
Conditions: Hereditary Angioedema
Register for Updates
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051
Recruiting
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Salt Lake City, Utah
Conditions: Neoplasms
Register for Updates
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685
Recruiting
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. Parts 1 and 2 will enroll patients with ISM. Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part.... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
11/08/2024
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
Register for Updates